Sarepta (SRPT +1.8%)
inks an agreement with Codiak BioSciences aimed at designing and
developing engineered exosome therapeutics to deliver gene therapy, gene
editing and RNA technologies for neuromuscular diseases.
Naturally occurring particles called exosomes
shuffle molecular payloads between cells, facilitating intercellular
communication. Codiak Biosciences’ focus is using those nanoparticles
for safe delivery of medicines to specific cell types via leveraging its
engEx platform
The two-year deal includes up to five targets.
Codiak is eligible to receive up to $72.5M in upfront and license fee
payments plus research funding. Sarepta has the exclusive option to
license any of the candidates.
If Sarepta exercises an option, Codiak will be
responsible till the IND phase while Sarepta will be responsible for
clinical development and commercialization.
https://seekingalpha.com/news/3585138-sarepta-teams-up-codiak-biosciences-in-neuromuscular-diseases
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.